French maritime pine bark extract (Pycnogenol®) reduces thromboxane generation in blood from diabetic male rats

Biomedicine and Pharmacotherapy

Volumn 62, Issue 3, 2008, Pages 168-172

  Nocun, Marek ^a,b   Ulicna, Olga ^c   Muchova, Jana ^c   Durackova, Zdenka ^c   Watala, Cezary ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b NOFER INSTITUTE OF OCCUPATIONAL MEDICINE   (Poland)

^c Bratislava   (Slovakia)

Author keywords

Experimental diabetes; Pycnogenol ; Thromboxane generation

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID DERIVATIVE; C PEPTIDE; DEXTRO LYSINE ACETYLSALICYLIC ACID; GLUCOSE; LASPAL; PLANT EXTRACT; PYCNOGENOL; THROMBOXANE A2; THROMBOXANE B2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BARK; BLOOD CHEMISTRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL RAT; FATTY ACID BLOOD LEVEL; FATTY ACID SYNTHESIS; GLUCOSE BLOOD LEVEL; INHIBITION KINETICS; INSULIN DEPENDENT DIABETES MELLITUS; MALE; METABOLITE; NONHUMAN; PINE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; STREPTOZOCIN DIABETES;

ANIMALS; ASPIRIN; BLOOD GLUCOSE; BODY WEIGHT; C-PEPTIDE; CYCLOOXYGENASE INHIBITORS; DIABETES MELLITUS, EXPERIMENTAL; FLAVONOIDS; MALE; PLANT EXTRACTS; RATS; RATS, WISTAR; THROMBOXANE B2; THROMBOXANES;

EID: 40749146015     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2007.07.002     Document Type: Article

References (31)

1. ®, French maritime pine bark extract. In: Coates P.M., BlackMan M.R., Cragg G., Levine M., Moss J., and White J. (Eds). Encyclopedia of dietary supplements (2005), Marcel Dekker, New York 545-553
2. Devaraj S., Vega-Lopez S., Kaul N., Schonlau F., Rohdewald P., and Jialal I. Supplementation with a pine bark extract rich in polyphenols increases plasma antioxidant capacity and alters the plasma lipoprotein profile. Lipids 37 (2002) 931-934
3. ® with ascorbic acid and trolox on the oxidation of lipids and proteins. Gen Physiol Biophys 25 (2006) 379-396
4. Cho K.J., Yun C.H., Yoon D.Y., Cho Y.S., Rimbach G., Packer L., et al. Effect of bioflavonoids extracted from the bark of Pinus maritima on proinflammatory cytokine interleukin-1 production in lipopolysaccharide-stimulated RAW 264.7. Toxicol Appl Pharmacol 168 (2000) 64-71
5. Peng Q., Wei Z., and Lau B.H. Pycnogenol inhibits tumor necrosis factor-alpha-induced nuclear factor kappa B activation and adhesion molecule expression in human vascular endothelial cells. Cell Mol Life Sci 57 (2000) 834-841
6. Cesarone M.R., Belcaro G., Rohdewald P., Pellegrini L., Ledda A., Vinciguerra G., et al. Comparison of Pycnogenol and Daflon in treating chronic venous insufficiency: a prospective, controlled study. Clin Appl Thromb Hemost 12 (2006) 205-212
7. Spadea L., and Balestrazzi E. Treatment of vascular retinopathies with Pycnogenol. Phytother Res 15 (2001) 219-223
8. Belcaro G., Cesarone M.R., Errichi B.M., Ledda A., Di Renzo A., Stuard S., et al. Diabetic ulcers: microcirculatory improvement and faster healing with pycnogenol. Clin Appl Thromb Hemost 12 (2006) 318-323
9. Fitzpatrick D.F., Bing B., and Rohdewald P. Endothelium-dependent vascular effects of Pycnogenol. J Cardiovasc Pharmacol 32 (1998) 509-515
10. Liu X., Wei J., Tan F., Zhou S., Wurthwein G., and Rohdewald P. Pycnogenol, French maritime pine bark extract, improves endothelial function of hypertensive patients. Life Sci 74 (2004) 855-862
11. Putter M., Grotemeyer K.H., Wurthwein G., Araghi-Niknam M., Watson R.R., Hosseini S., et al. Inhibition of smoking-induced platelet aggregation by aspirin and pycnogenol. Thromb Res 95 (1999) 155-161
12. Araghi-Niknam M., Hosseini S., Larson D., Rohdewald P., and Watson R.R. Pine bark extract reduces platelet aggregation. Integr Med 2 (2000) 73-77
13. Golanski J., Muchova J., Golanski R., Durackova Z., Markuszewski L., and Watala C. Does pycnogenol intensify the efficacy of acetylsalicylic acid in the inhibition of platelet function? In vitro experience. Postepy Hig Med Dosw 60 (2006) 316-321
14. Fateh-Moghadam S., Plockinger U., Cabeza N., Htun P., Reuter T., Ersel S., et al. Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol 42 (2005) 99-103
15. 2 and prostacyclin. Prostaglandins 40 (1990) 297-310
16. Murphy R.C., and FitzGerald G.A. Current approaches to estimation of eicosanoid formation in vivo. Adv Prostaglandin Thromboxane Leukot Res 22 (1994) 341-348
17. Manach C., Williamson G., Morand C., Scalbert A., and Remesy C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 81 (2005) 230S-242S
18. Williamson G., and Manach C. Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies. Am J Clin Nutr 81 (2005) 243S-255S
19. Rasmussen S.E., Frederiksen H., Struntze K.K., and Poulsen L. Dietary proanthocyanidins: occurrence, dietary intake, bioavailability, and protection against cardiovascular disease. Mol Nutr Food Res 49 (2005) 159-174
20. Chang W.C., and Hsu F.L. Inhibition of platelet aggregation and arachidonate metabolism in platelets by procyanidins. Prostaglandins Leukot Essent Fatty Acids 38 (1989) 181-188
21. Son D.J., Cho M.R., Jin Y.R., Kim S.Y., Park Y.H., Lee S.H., et al. Antiplatelet effect of green tea catechins: a possible mechanism through arachidonic acid pathway. Prostaglandins Leukot Essent Fatty Acids 71 (2004) 25-31
22. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 340 (1999) 115-126
23. Hsi E.D., and Remick D.G. Monocytes are the major producers of interleukin-1 beta in an ex vivo model of local cytokine production. J Interferon Cytokine Res 15 (1995) 89-94
24. Ristimaki A., Garfinkel S., Wessendorf J., Maciag T., and Hla T. Induction of cyclooxygenase-2 by interleukin-1 alpha. Evidence for post-transcriptional regulation. J Biol Chem 269 (1994) 11769-11775
25. Huang Z.F., Massey J.B., and Via D.P. Differential regulation of cyclooxygenase-2 (COX-2) mRNA stability by interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha) in human in vitro differentiated macrophages. Biochem Pharmacol 59 (2000) 187-194
26. Hankey G.J., and Eikelboom J.W. Aspirin resistance. Lancet 367 (2006) 606-617
27. Cho K.J., Yun C.H., Packer L., and Chung A.S. Inhibition mechanisms of bioflavonoids extracted from the bark of Pinus maritima on the expression of proinflammatory cytokines. Ann N Y Acad Sci 928 (2001) 141-156
28. Schafer A., Chovanova Z., Muchova J., Sumegova K., Liptakova A., Durackova Z., et al. Inhibition of COX-1 and COX-2 activity by plasma of human volunteers after ingestion of French maritime pine bark extract (Pycnogenol). Biomed Pharmacother 60 (2006) 5-9
29. Barbieri S.S., and Weksler B.B. Tobacco smoke cooperates with interleukin-1 beta to alter beta catenin trafficking in vascular endothelium resulting in increased permeability and induction of cyclooxygenase-2 expression in vitro and in vivo. FASEB J 21 (2007) 1831-1843
30. Liu X., Wei J., Tan F., Zhou S., Wurthwein G., and Rohdewald P. Antidiabetic effect of Pycnogenol French maritime pine bark extract in patients with diabetes type II. Life Sci 75 (2004) 2505-2513
31. Maritim A., Dene B.A., Sanders R.A., and Watkins III J.B. Effects of pycnogenol treatment on oxidative stress in streptozotocin-induced diabetic rats. J Biochem Mol Toxicol 17 (2003) 193-199